Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBTNASDAQ:ALLKNASDAQ:KZRNASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$3.71+0.3%$3.96$2.11▼$21.60$7.03M0.16518,653 shs3,329 shsALLKAllakos$0.33$0.31$0.22▼$1.56$29.74M0.151.17 million shsN/AKZRKezar Life Sciences$4.14-0.7%$4.30$3.62▼$9.18$30.25M0.6156,909 shs3,316 shsOKUROnKure Therapeutics$2.49-2.4%$2.83$1.70▼$20.00$33.64M0.4112,495 shs116,862 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare0.00%-4.69%-2.14%-49.52%-14.54%ALLKAllakos0.00%0.00%+0.95%+17.62%-74.09%KZRKezar Life Sciences+3.22%+4.25%-5.01%-26.97%-39.45%OKUROnKure Therapeutics+4.51%+18.60%+0.79%-49.70%+254,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.1205 of 5 stars0.05.00.04.32.91.70.0ALLKAllakos4.6051 of 5 stars3.15.00.04.72.72.51.3KZRKezar Life Sciences4.5107 of 5 stars3.25.00.04.62.92.50.6OKUROnKure Therapeutics3.0884 of 5 stars3.70.00.00.02.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/AALLKAllakos 2.20Hold$2.00507.72% UpsideKZRKezar Life Sciences 2.33Hold$39.50854.11% UpsideOKUROnKure Therapeutics 3.33Buy$32.331,198.53% UpsideCurrent Analyst Ratings BreakdownLatest ALBT, ALLK, OKUR, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/18/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.003/11/2025OKUROnKure TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $30.002/28/2025KZRKezar Life SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Outperform(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.37M5.13N/AN/A($17.22) per share-0.22ALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AKZRKezar Life Sciences$7M4.32N/AN/A$25.80 per share0.16OKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$16.71M-$19.96N/A∞N/A-1,125.59%N/A-73.69%8/18/2025 (Estimated)ALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)KZRKezar Life Sciences-$101.87M-$10.82N/AN/AN/AN/A-54.95%-46.11%8/12/2025 (Estimated)OKUROnKure Therapeutics-$77.39M-$5.26N/AN/AN/AN/A-51.17%-47.11%8/12/2025 (Estimated)Latest ALBT, ALLK, OKUR, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/A3/10/2025Q4 2024OKUROnKure Therapeutics-$0.86-$1.37-$0.51-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/AALLKAllakosN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.110.11ALLKAllakosN/A6.086.08KZRKezar Life Sciences0.057.657.65OKUROnKure TherapeuticsN/A23.7123.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%ALLKAllakos84.64%KZRKezar Life Sciences67.90%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%ALLKAllakos16.12%KZRKezar Life Sciences10.40%OKUROnKure Therapeutics2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million686,000Not OptionableALLKAllakos19090.38 million74.94 millionOptionableKZRKezar Life Sciences607.31 million6.62 millionNot OptionableOKUROnKure TherapeuticsN/A13.51 million2.75 millionN/AALBT, ALLK, OKUR, and KZR HeadlinesRecent News About These CompaniesOnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Consensus PT from AnalystsMay 28 at 1:51 AM | americanbankingnews.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 1,813,439 SharesMay 21, 2025 | americanbankingnews.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure increased R&D spending in 1Q with drug trials underwayMay 7, 2025 | bizwest.comOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%April 6, 2025 | aaii.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 12, 2025 | tipranks.comOnKure boosts R&D spending with cancer trial underwayMarch 12, 2025 | bizwest.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBT, ALLK, OKUR, and KZR Company DescriptionsAvalon GloboCare NASDAQ:ALBT$3.71 +0.01 (+0.27%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Allakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Kezar Life Sciences NASDAQ:KZR$4.14 -0.03 (-0.72%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.OnKure Therapeutics NASDAQ:OKUR$2.49 -0.06 (-2.35%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
